Showing results (1441-1450 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|November 27, 2012
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumorsDavid S Hong, Jennifer Hsing Choe, Aung Naing, et al.Investigational New Drugs|September 28, 2013
Ketoprofen-loaded polymeric nanocapsules selectively inhibit cancer cell growth in vitro and in preclinical model of glioblastoma multiformeElita F da Silveira, Janaine M Chassot, Fernanda C Teixeira, et al.Investigational New Drugs|October 12, 2013
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabineMatthew P Goetz, Heidi A McKean, Joel M Reid, et al.Investigational New Drugs|October 12, 2013
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitorConstance King, Henry Diaz, Darlene Barnard, et al.Investigational New Drugs|May 9, 2012
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell linesBrigette B Y Ma, Vivian W Y Lui, Crystal S Cheung, et al.Investigational New Drugs|January 1, 1997
Development of angiogenesis inhibitors for cancer therapyS G Eckhardt, J M PludaInvestigational New Drugs|January 1, 1997
An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of actionW J GradisharInvestigational New Drugs|May 1, 1993
Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatographyO van Tellingen, A V Kuijpers, J H Beijnen, et al.Investigational New Drugs|May 1, 1993
Chemotherapy of mammary carcinomas arising in ras transgenic miceD L Dexter, M Diamond, J Creveling, et al.Investigational New Drugs|May 1, 1993
A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumorsD R Adkins, R Irvin, J Kuhn, et al.Pageof 372